

## Dissertaties/PhD Theses 2014

- 01-2014 Thesis E. van der Vries, Erasmus University Rotterdam "Influenza Resistance to Antiviral Drugs - Virus characterization, mechanism and clinical impact"
- 05-2014 Thesis H.A. Sukhrie, Erasmus University Rotterdam "Identifying sources and transmission routes of norovirus outbreaks, Molecular epidemiological methods as the basis for targeted prevention strategies "
- 06-2014 Thesis Dr. T. Nguyen, Erasmus University Rotterdam "Interactions between Paramyxoviruses and Bacteria: Implications for Pathogenesis and Intervention"
- 06-2014 Thesis Dr. C.A.M. van de Weg, Erasmus University Rotterdam "Immune Activation in the Pathogenesis of Dengue Virus Infection"
- 09-2014 Thesis Dr. A. de Goede, Erasmus University Rotterdam "HIV Immunotherapy: Host Immunity and Virus Evolution"
- 09-2014 Thesis Dr. S. van Boheemen, Erasmus University Rotterdam "Virus Discovery and Characterization using Next-Generation Sequencing"
- 10-2014 Thesis Dr. A. Fibriani, Erasmus University Rotterdam "HIV and hepatitis virus co-infection among injecting drug users in West Java, Indonesia"

## Other university

- 10-2014 Thesis Dr. J. van Dijk, Utrecht University "Pathogen dynamics in a partial migrant: interactions between mallards (*Anas platyrhynchos*) and avian influenza viruses"

---

## 2014 Koopmans

1. Cleton N, Reusken C, Murk JL, De Jong M, Reimerink J, Van Der Eijk A, **Koopmans M**. Using routine diagnostic data as a method of surveillance of arboviral infection in travellers: A comparative analysis with a focus on dengue. *Travel Medicine and Infectious Disease*. 2014;12(2):159-66.
2. Goeijenbier M, van Kampen JJ, Reusken CB, **Koopmans MP**, van Gorp EC. Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis. *Neth J Med*. 2014 Nov;72(9):442-8.
3. Teunis PF, Sukhrie FH, Vennema H, Bogerman J, Beersma MF, **Koopmans MP**. Shedding of norovirus in symptomatic and asymptomatic infections. *Epidemiol Infect*. 2014 Oct 22:1-8.
4. Fanoy EB, van der Sande MA, Kraaij-Dirkzwager M, Dirksen K, Jonges M, van der Hoek W, **Koopmans MP**, van der Werf D, Sonder G, van der Weijden C, van der Heuvel J, Gelinck L, Bouwhuis JW, van Gageldonk-Lafeber AB. Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014. *Emerg Themes Epidemiol*. 2014;11:16.
5. Kraaij-Dirkzwager M, Timen A, Dirksen K, Gelinck L, Leyten E, Groeneveld P, Jansen C, Jonges M, Raj S, Thurkow I, van Gageldonk-Lafeber R, van der Eijk A, **Koopmans M**. Middle east respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014. *Eurosurveillance*. 2014;19(21)
6. Reusken C, Haagmans BL, Koopmans MP. [Dromedary camels and Middle East respiratory syndrome: MERS coronavirus in the 'ship of the desert'] *Dromedaris en 'Middle East respiratory syndrome': MERS-coronavirus in het 'schip van de woestijn'*. *Ned Tijdschr Geneesk*. 2014;158:A7806.
7. Freidl GS, de Bruin E, van Beek J, Reimerink J, de Wit S, Koch G, Vervelde L, van den Ham HJ, **Koopmans MP**. Getting more out of less--a quantitative serological screening tool for simultaneous detection of multiple influenza A hemagglutinin-types in chickens. *PLoS One*. 2014;9(9):e108043.
8. Tijssen-Klasen E, **Koopmans MP**, Sprong H. Tick-borne pathogen - reversed and conventional discovery of disease. *Front Public Health*. 2014;2:73.
9. Reusken CB, Messadi L, Feyisa A, Ularamu H, Godeke GJ, Danmarwa A, Dawo F, Jemli M, Melaku S, Shamaki D, Woma Y, Wungak Y, Gebremedhin EZ, Zutt I, Bosch BJ, Haagmans BL, **Koopmans MP**.

Geographic distribution of MERS coronavirus among dromedary camels, Africa. *Emerg Infect Dis.* 2014 Aug;20(8):1370-4.

10. de Bruin E, Loeber JG, Meijer A, Castillo GM, Cepeda ML, Torres-Sepulveda MR, Borrajo GJ, Caggana M, Giguere Y, Meyer M, Fukushi M, Devi AR, Khneisser I, Vilarinho L, von Döbeln U, Torresani T, Mackenzie J, Zutt I, Schipper M, Elvers LH, **Koopmans MP**. Evolution of an influenza pandemic in 13 countries from 5 continents monitored by protein microarray from neonatal screening bloodspots. *J Clin Virol.* 2014 Sep;61(1):74-80.
11. van Asten L, Fanoy EB, Hooiveld M, **Koopmans MP**, Kretzschmar ME, Werkgroep inventarisatie s. [Syndromic surveillance: a finger on the pulse of public health] Syndroomsurveillance: een vinger aan de pols van de volksgezondheid. *Ned Tijdschr Geneeskd.* 2014;158:A7415.
12. Reusken CB, Farag EA, Jonges M, Godeke GJ, El-Sayed AM, Pas SD, Raj VS, Mohran KA, Moussa HA, Ghobashy H, Alhajri F, Ibrahim AK, Bosch BJ, Pasha SK, Al-Romaihi HE, Al-Thani M, Al-Marri SA, AlHajri MM, Haagmans BL, **Koopmans MP**. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. *Euro Surveill.* 2014;19(23).
13. Petrignani M, Verhoef L, Vennema H, van Hunen R, Baas D, van Steenberghe JE, **Koopmans MP**. Underdiagnosis of foodborne hepatitis A, The Netherlands, 2008-2010(1.). *Emerg Infect Dis.* 2014 Apr;20(4):596-602.
14. Meyer B, Muller MA, Corman VM, Reusken CB, Ritz D, Godeke GJ, Lattwein E, Kallies S, Siemens A, van Beek J, Drexler JF, Muth D, Bosch BJ, Wernery U, **Koopmans MP**, Wernery R, Drosten C. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. *Emerg Infect Dis.* 2014 Apr;20(4):552-9.
15. te Beest D, de Bruin E, Imholz S, Wallinga J, Teunis P, **Koopmans M**, van Boven M. PLoS One. 2014 Nov 18;9(11):e113021. Discrimination of influenza infection (A/2009 H1N1) from prior exposure by antibody protein microarray analysis.
16. Ke C, Lu J, Wu J, Guan D, Zou L, Song T, Yi L, Zeng X, Liang L, Ni H, Kang M, Zhang X, Zhong H, He J, Lin J, Smith D, Burke D, Fouchier RA, **Koopmans M**, Zhang Y. Circulation of reassortant influenza A(H7N9) viruses in poultry and humans, Guangdong Province, China, 2013. *Emerg Infect Dis.* 2014 Dec;20(12):2034-40.
17. Welkers, M.R., Jonges, M., Jeeninga, R.E., **Koopmans, M.P.**, de Jong, M.D. Improved detection of artifactual viral minority variants in high-throughput sequencing data. *Front Microbiol.* 2014. 5: p. 804.
18. Jonges M, Welkers MR, Jeeninga RE, Meijer A, Schneeberger P, Fouchier RA, de Jong MD, **Koopmans M**. Emergence of the virulence-associated PB2 E627K substitution in a fatal human case of highly pathogenic avian influenza virus A(H7N7) infection as determined by Illumina ultra-deep sequencing. *J Virol.* 2014 Feb;88(3):1694-702.
19. de Jong MD, Reusken C, Horby P, **Koopmans M**, Bonten M, Chiche JD, Giaquinto C, Welte T, Leus F, Schotsman J, Goossens H, on behalf of the PREPARE consortium and affiliated clinical networks. Preparedness for admission of patients with suspected Ebola virus disease in European hospitals: a survey, August-September 2014. *Euro Surveill.* 2014;19(48)
20. de Jong MD, **Koopmans M**, Goossens H, on behalf of the authors of the original article. Authors' reply: Management of patients with Ebola virus disease in Europe: high-level isolation units should have a key role. *Euro Surveill.* 2014;19(50)
21. Haagmans BL, Al Dhahiry SH, Reusken CB, Raj VS, Galiano M, Myers R, Godeke GJ, Jonges M, Farag E, Diab A, Ghobashy H, Alhajri F, Al-Thani M, Al-Marri SA, Al Romaihi HE, Al Khal A, Birmingham A, Osterhaus AD, AlHajri MM, **Koopmans MP**. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. *Lancet Infect Dis.* 2014 Feb;14(2):140-5.
22. Raj VS, Farag EA, Reusken CB, Lamers MM, Pas SD, Voermans J, Smits SL, Osterhaus AD, Al-Mawlawi N, Al-Romaihi HE, AlHajri MM, El-Sayed AM, Mohran KA, Ghobashy H, Alhajri F, Al-Thani M, Al-Marri SA, El-Maghraby MM, **Koopmans MP**, Haagmans BL. Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. *Emerg Infect Dis.* 2014 Aug;20(8):1339-42.
23. Smits SL, Schapendonk CM, van Beek J, Vennema H, Schurch AC, Schipper D, Bodewes R, Haagmans BL, Osterhaus AD, **Koopmans MP**. New viruses in idiopathic human diarrhea cases, the Netherlands. *Emerg Infect Dis.* 2014 Jul;20(7):1218-22.
24. Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A, Koulouris NG, Osterhaus AD, **Koopmans MP**, Tsakris A. Virological and serological analysis of a recent Middle East respiratory

syndrome coronavirus infection case on a triple combination antiviral regimen. *Int J Antimicrob Agents*. 2014 Dec;44(6):528-32.

25. Goeijenbier M, Hartskeerl RA, Reimerink J, Verner-Carlsson J, Wagenaar JF, Goris MG, Martina BE, Lundkvist A, **Koopmans M**, Osterhaus AD, van Gorp EC, Reusken CB. The hanta hunting study: underdiagnosis of Puumala hantavirus infections in symptomatic non-travelling leptospirosis-suspected patients in the Netherlands, in 2010 and April to November 2011. *Euro Surveill*. 2014;19(32).

---

## **Osterhaus**

26. Bodewes R, Hapsari R, Rubio Garcia A, Sanchez Contreras GJ, van de Bildt MW, de Graaf M, Kuiken T, **Osterhaus AD**. Molecular epidemiology of seal parvovirus, 1988-2014. *PLoS One* 2014;9(11):e112129.
27. Bodewes R, Lapp S, Hahn K, Habierski A, Forster C, Konig M, Wohlsein P, **Osterhaus AD**, Baumgartner W. Novel canine bocavirus strain associated with severe enteritis in a dog litter. *Vet Microbiol*. 2014 Nov 7;174(1-2):1-8.
28. Bodewes R, Lempp C, Schurch AC, Habierski A, Hahn K, Lamers M, von Dornberg K, Wohlsein P, Drexler JF, Haagmans BL, Smits SL, Baumgartner W, **Osterhaus AD**. Novel divergent nidovirus in a python with pneumonia. *J Gen Virol*. 2014 Nov;95(Pt 11):2480-5.
29. Bodewes R, Raj VS, Kik MJ, Schapendonk CM, Haagmans BL, Smits SL, **Osterhaus AD**. Updated phylogenetic analysis of arenaviruses detected in boid snakes. *J Virol*. 2014 Jan;88(2):1399-400.
30. Bodewes R, Ruiz-Gonzalez A, Schapendonk CM, van den Brand JM, **Osterhaus AD**, Smits SL. Viral metagenomic analysis of feces of wild small carnivores. *Virol J*. 2014;11:89.
31. Bodewes R, Ruiz-Gonzalez A, Schurch AC, **Osterhaus AD**, Smits SL. Novel divergent rhabdovirus in feces of red fox, Spain. *Emerg Infect Dis*. 2014 Dec;20(12):2172-4.
32. Bodewes R, Sanchez Contreras GJ, Rubio Garcia A, Hapsari R, van de Bildt MW, Kuiken T, **Osterhaus AD**. Identification of DNA sequences that imply a novel gammaherpesvirus in seals. *J Gen Virol*. 2014 Dec 18.
33. Bodewes R, van de Bildt MW, van Elk CE, Bunskoek PE, van de Vijver DA, Smits SL, **Osterhaus AD**, Kuiken T. No serological evidence that harbour porpoises are additional hosts of influenza B viruses. *PLoS One*. 2014;9(2):e89058.
34. de Goede AL, Vulto AG, **Osterhaus AD**, Gruters RA. Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIV. *Ann Pharm Fr*. 2014 Dec 17.
35. de Goede AL, Vulto AG, **Osterhaus AD**, Gruters RA. Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection. *Ann Pharm Fr*. 2014 Dec 11.
36. de Vries RD, Ludlow M, Verburgh RJ, van Amerongen G, Yuksel S, Nguyen DT, McQuaid S, **Osterhaus AD**, Duprex WP, de Swart RL. Measles vaccination of nonhuman primates provides partial protection against infection with canine distemper virus. *J Virol*. 2014 Apr;88(8):4423-33.
37. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones TC, Le NM, Pham QT, Tran ND, Wong Y, Mosterin A, Katzelnick LC, Labonte D, Le TT, van der Net G, Skepner E, Russell CA, Kaplan TD, Rimmelzwaan GF, Masurel N, de Jong JC, Palache A, Beyer WE, Le QM, Nguyen TH, Wertheim HF, Hurt AC, **Osterhaus AD**, Barr IG, Fouchier RA, Horby PW, Smith DJ. Antibody landscapes after influenza virus infection or vaccination. *Science*. 2014 Nov 21;346(6212):996-1000.
38. Fooks AR, Koraka P, de Swart RL, Rupprecht CE, **Osterhaus AD**. Development of a multivalent paediatric human vaccine for rabies virus in combination with Measles-Mumps-Rubella (MMR). *Vaccine*. 2014 Apr 11;32(18):2020-1.
39. Fraiser C, Koraka P, Belghazi M, Bakli M, Granjeaud S, Pophillat M, Lim SM, **Osterhaus A**, Martina B, Camoin L, Almeras L. Kinetic analysis of mouse brain proteome alterations following Chikungunya virus infection before and after appearance of clinical symptoms. *PLoS One*. 2014;9(3):e91397.
40. Goeijenbier M, van Gorp EC, Van den Brand JM, Stittelaar K, Bakhtiari K, Roelofs JJ, van Amerongen G, Kuiken T, Martina BE, Meijers JC, **Osterhaus AD**. Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. *BMC Microbiol*. 2014;14:134.

41. Haagmans BL, **Osterhaus AD**. Neutralizing the MERS coronavirus threat. *Sci Transl Med*. 2014 May 7;6(235):235fs19.
42. Hillaire ML, van Eijk M, Vogelzang-van Trierum SE, Fouchier RA, **Osterhaus AD**, Haagsman HP, Rimmelzwaan GF. Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo. *Virus Res*. 2014 Mar 6;181:22-6.
43. Hou J, van Oord G, Groothuismink ZM, Claassen MA, Kreefft K, Zaaraoui-Boutahar F, van IWF, **Osterhaus AD**, Janssen HL, Andeweg AC, de Knecht RJ, Boonstra A. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection. *J Virol*. 2014 Nov;88(21):12254-64.
44. Jungwirth N, Bodewes R, **Osterhaus AD**, Baumgartner W, Wohlsein P. First report of a new alphaherpesvirus in a freshwater turtle (*Pseudemys concinna concinna*) kept in Germany. *Vet Microbiol*. 2014 Jun 4;170(3-4):403-7.
45. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, **Osterhaus AD**, Haagmans BL, Gambotto A. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. *Vaccine*. 2014 Oct 14;32(45):5975-82.
46. Koel BF, van der Vliet S, Burke DF, Bestebroer TM, Bharoto EE, Yasa IW, Herliana I, Laksono BM, Xu K, Skepner E, Russell CA, Rimmelzwaan GF, Perez DR, **Osterhaus AD**, Smith DJ, Prajitno TY, Fouchier RA. Antigenic variation of clade 2.1 H5N1 virus is determined by a few amino acid substitutions immediately adjacent to the receptor binding site. *MBio*. 2014;5(3):e01070-14.
47. Koraka P, Bosch BJ, Cox M, Chubet R, Amerongen G, Lovgren-Bengtsson K, Martina BE, Roose J, Rottier PJ, **Osterhaus AD**. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice. *Vaccine*. 2014 Aug 6;32(36):4644-50.
48. Kreijtz JH, Goeijenbier M, Moesker FM, van den Dries L, Goeijenbier S, De Gruyter HL, Lehmann MH, Mutsert G, van de Vijver DA, Volz A, Fouchier RA, van Gorp EC, Rimmelzwaan GF, Sutter G, **Osterhaus AD**. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. *Lancet Infect Dis*. 2014 Dec;14(12):1196-207.
49. Kreijtz JH, Wiersma LC, De Gruyter HL, Vogelzang-van Trierum SE, van Amerongen G, Stittelaar KJ, Fouchier RA, **Osterhaus AD**, Sutter G, Rimmelzwaan GF. A Single Immunization With Modified Vaccinia Virus Ankara-Based Influenza Virus H7 Vaccine Affords Protection in the Influenza A(H7N9) Pneumonia Ferret Model. *J Infect Dis*. 2014 Sep 22.
50. Latorre-Margalef N, Tolf C, Grosbois V, Avril A, Bengtsson D, Wille M, **Osterhaus AD**, Fouchier RA, Olsen B, Waldenstrom J. Long-term variation in influenza A virus prevalence and subtype diversity in migratory mallards in northern Europe. *Proc Biol Sci*. 2014 Apr 22;281(1781):20140098.
51. Lim SM, Brault AC, van Amerongen G, Sewbalaksing VD, **Osterhaus AD**, Martina BE, Koraka P. Susceptibility of European jackdaws (*Corvus monedula*) to experimental infection with lineage 1 and 2 West Nile viruses. *J Gen Virol*. 2014 Jun;95(Pt 6):1320-9.
52. Linster M, van Boheemen S, de Graaf M, Schrauwen EJ, Lexmond P, Manz B, Bestebroer TM, Baumann J, van Riel D, Rimmelzwaan GF, **Osterhaus AD**, Matrosovich M, Fouchier RA, Herfst S. Identification, characterization, and natural selection of mutations driving airborne transmission of A/H5N1 virus. *Cell*. 2014 Apr 10;157(2):329-39.
53. Maltais AK, Stittelaar KJ, Veldhuis Kroeze EJ, van Amerongen G, Dijkshoorn ML, Krestin GP, Hinkula J, Arwidsson H, Lindberg A, **Osterhaus AD**. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets. *Vaccine*. 2014 May 30;32(26):3307-15.
54. Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, de Waal L, Veldhuis Kroeze EJ, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, **Osterhaus AD**, Knight A, Oxford JS, Lapini G, Cox R, Lambkin-Williams R. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. *PLoS One*. 2014;9(5):e93761.
55. Murk JL, de Vries AC, GeurtsvanKessel CH, Aron G, **Osterhaus AD**, Wolthers KC, Fraaij PL. Persistent spiking fever in a child with acute myeloid leukemia and disseminated infection with enterovirus. *J Clin Virol*. 2014 Nov;61(3):453-5.

56. Ouwendijk WJ, Geluk A, Smits SL, Getu S, **Osterhaus AD**, Verjans GM. Functional characterization of ocular-derived human alphaherpesvirus cross-reactive CD4 T cells. *J Immunol.* 2014 Apr 15;192(8):3730-9.
57. Prachayangprecha S, Schapendonk CM, Koopmans MP, **Osterhaus AD**, Schurch AC, Pas SD, van der Eijk AA, Poovorawan Y, Haagmans BL, Smits SL. Exploring the potential of next-generation sequencing in detection of respiratory viruses. *J Clin Microbiol.* 2014 Oct;52(10):3722-30.
58. Raj VS, **Osterhaus AD**, Fouchier RA, Haagmans BL. MERS: emergence of a novel human coronavirus. *Curr Opin Virol.* 2014 Apr;5:58-62.
59. Raj VS, Smits SL, Provacia LB, van den Brand JM, Wiersma L, Ouwendijk WJ, Bestebroer TM, Spronken MI, van Amerongen G, Rottier PJ, Fouchier RA, Bosch BJ, **Osterhaus AD**, Haagmans BL. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. *J Virol.* 2014 Feb;88(3):1834-8.
60. Ramis A, van Amerongen G, van de Bildt M, Leijten L, Vanderstichel R, **Osterhaus A**, Kuiken T. Experimental infection of highly pathogenic avian influenza virus H5N1 in black-headed gulls (*Chroicocephalus ridibundus*). *Vet Res.* 2014;45:84.
61. Reperant LA, Kuiken T, Grenfell BT, **Osterhaus AD**. The immune response and within-host emergence of pandemic influenza virus. *Lancet.* 2014 Dec 6;384(9959):2077-81.
62. Reperant LA, **Osterhaus AD**. Dromedary MERS-CoV replicates in human respiratory tissues. *Lancet Respir Med.* 2014 Oct;2(10):779-81.
63. Reperant LA, Rimmelzwaan GF, **Osterhaus AD**. Advances in influenza vaccination. *F1000Prime Rep.* 2014;6:47.
64. Reperant LA, van de Burgwal LH, Claassen E, **Osterhaus AD**. Ebola: public-private partnerships. *Science.* 2014 Oct 24;346(6208):433-4.
65. Schaftenaar E, van Gorp EC, Meenken C, Osterhaus AD, Remeijer L, Struthers HE, McIntyre JA, Baarsma GS, Verjans GM, Peters RP. Ocular infections in sub-Saharan Africa in the context of high HIV prevalence. *Trop Med Int Health.* 2014 Sep;19(9):1003-14.
66. Schaftenaar E, Verjans GM, Getu S, McIntyre JA, Struthers HE, **Osterhaus AD**, Peters RP. High seroprevalence of human herpesviruses in HIV-infected individuals attending primary healthcare facilities in rural South Africa. *PLoS One.* 2014;9(6):e99243.
67. Schrauwen EJ, de Graaf M, Herfst S, Rimmelzwaan GF, **Osterhaus AD**, Fouchier RA. Determinants of virulence of influenza A virus. *Eur J Clin Microbiol Infect Dis.* 2014 Apr;33(4):479-90.
68. Schurch AC, Schipper D, Bijl MA, Dau J, Beckmen KB, Schapendonk CM, Raj VS, **Osterhaus AD**, Haagmans BL, Tryland M, Smits SL. Metagenomic survey for viruses in Western Arctic caribou, Alaska, through iterative assembly of taxonomic units. *PLoS One.* 2014;9(8):e105227.
69. Siegers JY, Short KR, Leijten LM, de Graaf M, Spronken MI, Schrauwen EJ, Marshall N, Lowen AC, Gabriel G, **Osterhaus AD**, Kuiken T, van Riel D. Novel avian-origin influenza A (H7N9) virus attachment to the respiratory tract of five animal models. *J Virol.* 2014 Apr;88(8):4595-9.
70. Siegers JY, van de Bildt MW, van Elk CE, Schurch AC, Tordo N, Kuiken T, Bodewes R, **Osterhaus AD**. Genetic relatedness of dolphin rhabdovirus with fish rhabdoviruses. *Emerg Infect Dis.* 2014 Jun;20(6):1081-2.
71. Smits SL, Bodewes R, Ruiz-Gonzalez A, Baumgartner W, Koopmans MP, **Osterhaus AD**, Schurch AC. Assembly of viral genomes from metagenomes; 2014. Report No.: 1664-302X (Electronic)
72. Strayer DR, Carter WA, Stouch BC, Stittelaar KJ, Thoolen RJ, **Osterhaus AD**, Mitchell WM. Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-alpha administered to the buccal mucosa. *Antiviral Res.* 2014 Oct;110:175-80.
73. van Baalen CA, Els C, Sprong L, van Beek R, van der Vries E, **Osterhaus AD**, Rimmelzwaan GF. Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture. *J Clin Microbiol.* 2014 May;52(5):1672-7.
74. van de Sandt CE, Kreijtz JH, de Mutsert G, Geelhoed-Mieras MM, Hillaire ML, Vogelzang-van Trierum SE, **Osterhaus AD**, Fouchier RA, Rimmelzwaan GF. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. *J Virol.* 2014 Feb;88(3):1684-93.

75. van de Sandt CE, Kreijtz JH, Geelhoed-Mieras MM, Vogelzang-van Trierum SE, Nieuwkoop NJ, van de Vijver DA, Fouchier RA, **Osterhaus AD**, Morein B, Rimmelzwaan GF. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine. *Vaccine*. 2014 Sep 29;32(43):5614-23.
76. van de Weg CA, Huits RM, Pannuti CS, Brouns RM, van den Berg RW, van den Ham HJ, Martina BE, **Osterhaus AD**, Netea MG, Meijers JC, van Gorp EC, Kallas EG. Hyperferritinaemia in dengue virus infected patients is associated with immune activation and coagulation disturbances. *PLoS Negl Trop Dis*. 2014 Oct;8(10):e3214.
77. van de Weg CA, Pannuti CS, van den Ham HJ, de Araujo ES, Boas LS, Felix AC, Carvalho KI, Levi JE, Romano CM, Centrone CC, Rodrigues CL, Luna E, van Gorp EC, **Osterhaus AD**, Kallas EG, Martina BE. Serum angiopoietin-2 and soluble VEGF receptor 2 are surrogate markers for plasma leakage in patients with acute dengue virus infection. *J Clin Virol*. 2014 Aug;60(4):328-35.
78. van den Brand JM, Haagmans BL, van Riel D, **Osterhaus AD**, Kuiken T. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. *J Comp Pathol*. 2014 Jul;151(1):83-112.
79. van den Doel P, Volz A, Roose JM, Sewbalaksing VD, Pijlman GP, van Middelkoop I, Duiverman V, van de Wetering E, Sutter G, **Osterhaus AD**, Martina BE. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. *PLoS Negl Trop Dis*. 2014 Sep;8(9):e3101.
80. van den Hoogen BG, van Boheemen S, de Rijck J, van Nieuwkoop S, Smith DJ, Laksono B, Gultyaev A, **Osterhaus AD**, Fouchier RA. Excessive production and extreme editing of human metapneumovirus defective interfering RNA is associated with type I IFN induction. *J Gen Virol*. 2014 Aug;95(Pt 8):1625-33.
81. van Elk CE, van de Bildt MW, Jauniaux T, Hiemstra S, van Run PR, Foster G, Meerbeek J, **Osterhaus AD**, Kuiken T. Is dolphin morbillivirus virulent for white-beaked dolphins (*Lagenorhynchus albirostris*)? *Vet Pathol*. 2014 Nov;51(6):1174-82.
82. van Riel D, Leijten LM, Verdijk RM, GeurtsvanKessel C, van der Vries E, van Rossum AM, **Osterhaus AD**, Kuiken T. Evidence for influenza virus CNS invasion along the olfactory route in an immunocompromised infant. *J Infect Dis*. 2014 Aug 1;210(3):419-23.
83. Verhagen JH, Majoor F, Lexmond P, Vuong O, Kasemir G, Lutterop D, **Osterhaus AD**, Fouchier RA, Kuiken T. Epidemiology of influenza A virus among black-headed gulls, the Netherlands, 2006-2010. *Emerg Infect Dis*. 2014 Jan;20(1):138-41.
84. Westgeest KB, Russell CA, Lin X, Spronken MI, Bestebroer TM, Bahl J, van Beek R, Skepner E, Halpin RA, de Jong JC, Rimmelzwaan GF, **Osterhaus AD**, Smith DJ, Wentworth DE, Fouchier RA, de Graaf M. Genomewide analysis of reassortment and evolution of human influenza A(H3N2) viruses circulating between 1968 and 2011. *J Virol*. 2014 Mar;88(5):2844-57.
85. Wiersma LC, Vogelzang-van Trierum SE, van Amerongen G, van Run P, Nieuwkoop NJ, Ladwig M, Banneke S, Schaefer H, Kuiken T, Fouchier RA, **Osterhaus AD**, Rimmelzwaan GF. Pathogenesis of Infection with 2009 Pandemic H1N1 Influenza Virus in Isogenic Guinea Pigs after Intranasal or Intratracheal Inoculation. *Am J Pathol*. 2014 Dec 31.
86. Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, Wylock C, De Bel AV, Vandelloo J, Pistoro F, Heirman C, Beyer WEP, Eilers PHC, Corthals J, Padmos I, Thielemans K, **Osterhaus ADME**, Lacor P, van der Ende ME, Aerts JL, van Baalen CA, Gruters RA. Corrigendum to 'A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption' [*Clin. Immunol*. 142 (2012) 252-268]. *Clinical Immunology*. 2014;150(1):88-9.
87. Pronker E, Weenen T, Commandeur H, Claassen E, **Osterhaus ADME**. Scratching the surface: Exploratory analysis of key opinion leaders on rate limiting factors in novel adjuvanted-vaccine development. *Technological Forecasting and Social Change*. 2014.

#### **Other – Fouchier**

88. Gilbert M, Koel BF, Bestebroer TM, Lewis NS, Smith DJ, **Fouchier RA**. Serological Evidence for Non-Lethal Exposures of Mongolian Wild Birds to Highly Pathogenic Avian Influenza H5N1 Virus. *PLoS One*. 2014;9(12):e113569.

89. van Boheemen S, **Fouchier RA**, Hajdarbegovic E. The Cause of Follicular Spicules in Multiple Myeloma-Reply. *JAMA Dermatol.* 2014 Dec 3.
90. Verhagen JH, van Dijk JG, Vuong O, Bestebroer T, Lexmond P, Klaassen M, **Fouchier RA**. Migratory birds reinforce local circulation of avian influenza viruses. *PLoS One.* 2014;9(11):e112366.
91. Buijs PR, van Amerongen G, van Nieuwkoop S, Bestebroer TM, van Run PR, Kuiken T, **Fouchier RA**, van Eijck CH, van den Hoogen BG. Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy. *Cancer Gene Ther.* 2014 Nov;21(11):463-71.
92. Couzens L, Gao J, Westgeest K, Sandbulte M, Lugovtsev V, **Fouchier R**, Eichelberger M. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. *J Virol Methods.* 2014 Sep 16;210C:7-14.
93. Gulyaev AP, Tsyganov-Bodounov A, Spronken MI, van der Kooij S, **Fouchier RA**, Olsthoorn RC. RNA structural constraints in the evolution of the influenza A virus genome NP segment. *RNA Biol.* 2014;11(7):942-52.
94. Herfst S, Imai M, Kawaoka Y, **Fouchier RA**. Avian influenza virus transmission to mammals. *Curr Top Microbiol Immunol.* 2014;385:137-55.
95. Herfst S, **Fouchier R**. Epidemiological and genetic investigations of human-to-human transmission of zoonotic influenza viruses. *Euro Surveill.* 2014;19(25).
96. Martin-Valls GE, Simon-Grife M, van Boheemen S, de Graaf M, Bestebroer TM, Busquets N, Martin M, Casal J, **Fouchier RA**, Mateu E. Phylogeny of Spanish swine influenza viruses isolated from respiratory disease outbreaks and evolution of swine influenza virus within an endemically infected farm. *Vet Microbiol.* 2014 Jun 4;170(3-4):266-77.
97. de Graaf M, **Fouchier RA**. Role of receptor binding specificity in influenza A virus transmission and pathogenesis. *EMBO J.* 2014 Apr 16;33(8):823-41.
98. Buijs PR, van Eijck CH, Hofland LJ, **Fouchier RA**, van den Hoogen BG. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. *Cancer Gene Ther.* 2014 Jan;21(1):24-30.
99. van Dijk JG, Hoyer BJ, Verhagen JH, Nolet BA, **Fouchier RA**, Klaassen M. Juveniles and migrants as drivers for seasonal epizootics of avian influenza virus. *J Anim Ecol.* 2014 Jan;83(1):266-75.

#### **Other – Boucher**

100. Pingen M, Sarrami-Forooshani R, Wensing A, van Ham P, Drewniak A, **Boucher C**, Geijtenbeek T, Nijhuis M. Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model. *Retrovirology.* 2014 Dec 14;11(1):113.
101. Berden FA, Kievit W, Baak LC, Bakker CM, Beuers U, **Boucher CA**, Brouwer JT, Burger DM, van Erpecum KJ, van Hoek B, Hoepelman AI, Honkoop P, Kerbert-Dreteler MJ, de Knegt RJ, Koek GH, van Nieuwkerk CM, van Soest H, Tan AC, Vrolijk JM, Drenth JP. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. *Neth J Med.* 2014 Oct;72(8):388-400.
102. Whitley, R.J., **Boucher, C.A.**, Lina, B. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The Influenza Resistance Information Study (IRIS) (*Clinical Infectious Diseases* (2013) 56 (1197-205))
103. Fibriani A, Wisaksana R, Alisjahbana B, Indrati A, Schutten M, van Crevel R, van der Ven A, **Boucher CA**. Hepatitis B virus prevalence, risk factors and genotype distribution in HIV infected patients from West Java, Indonesia. *J Clin Virol.* 2014 Apr;59(4):235-41.
104. Whitley, R.J., **Boucher, C.A.**, Lina, B. Erratum: Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The Influenza Resistance Information Study (IRIS) (*Clinical Infectious Diseases* (2013) 56 (1197-205)) (Erratum) *Clinical Infectious Diseases* Volume 58, Issue 8, 15 April 2014, Page 1203.
105. Frenzt D, van de Vijver D, Abecasis A, Albert J, Hamouda O, Jorgensen L, Kucherer C, Struck D, Schmit JC, Vercauteren J, Asjo B, Balotta C, Bergin C, Beshkov D, Camacho R, Clotet B, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis L, Linka KL, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stockl E, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, **Boucher C**, Wensing A, Programme S. Patterns of transmitted HIV drug resistance in Europe vary by risk group. *PLoS One.* 2014;9(4):e94495.

106. Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jorgensen LB, Kucherer C, Struck D, Schmit JC, Vercauteren J, Asjo B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stockl E, Sonnerborg A, Stanekova D, Stanojevic M, Van Wijngaerden E, Wensing AM, **Boucher CA**, Programme S. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. *BMC Infect Dis.* 2014;14:407.
107. Nichols BE, Baltussen R, van Dijk JH, Thuma PE, Nouwen JL, **Boucher CA**, van de Vijver DA. Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach. *J Acquir Immune Defic Syndr.* 2014 Jun 1;66(2):221-8.
108. Nichols BE, Sigaloff KC, Kityo C, Hamers RL, Baltussen R, Bertagnolio S, Jordan MR, Hallett TB, **Boucher CA**, de Wit TF, van de Vijver DA. Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study. *J Int AIDS Soc.* 2014;17:19164.
109. Pingen M, Wensing AM, Fransen K, De Bel A, de Jong D, Hoepelman AI, Magiorkinis E, Paraskevis D, Lunar MM, Poljak M, Nijhuis M, **Boucher CA**, programme S. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. *Retrovirology.* 2014;11:105.
110. Nichols BE, Sigaloff KC, Kityo C, Mandaliya K, Hamers RL, Bertagnolio S, Jordan MR, **Boucher CA**, Rinke de Wit TF, van de Vijver DA. Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study. *AIDS.* 2014 Jan 2;28(1):73-83.
111. Pineda-Pena AC, Schrooten Y, Vinken L, Ferreira F, Li G, Trovao NS, Khouri R, Derdelinckx I, De Munter P, Kucherer C, Kostrikis LG, Nielsen C, Liitsola K, Stanojevic M, Paredes R, Balotta C, Albert J, **Boucher C**, Gomez-Lopez A, Van Wijngaerden E, Van Ranst M, Vercauteren J, Vandamme AM, Van Laethem K. Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic. *PLoS One.* 2014;9(7):e101738.

#### **Other – Rimmelzwaan**

112. Jong W, Daleke-Schermerhorn MH, Vikstrom D, Ten Hagen-Jongman CM, de Punder K, van der Wel NN, van de Sandt CE, **Rimmelzwaan GF**, Follmann F, Agger E, Andersen P, de Gier JW, Luirink J. An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines. *Microb Cell Fact.* 2014 Nov 25;13(1):162.
113. Backer RA, Helbig C, Gentek R, Kent A, Laidlaw BJ, Dominguez CX, de Souza YS, van Trierum SE, van Beek R, **Rimmelzwaan GF**, ten Brinke A, Willemsen AM, van Kampen AH, Kaech SM, Blander JM, van Gisbergen K, Amsen D. A central role for Notch in effector CD8(+) T cell differentiation. *Nat Immunol.* 2014 Dec;15(12):1143-51.
114. Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, **Rimmelzwaan GF**, Sutter G, Volz A. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. *Viruses.* 2014 Jul;6(7):2735-61.

#### **Other – Kuiken**

115. Short KR, Veldhuis Kroeze EJ, Reperant LA, Richard M, **Kuiken T**. Influenza virus and endothelial cells: a species specific relationship. *Front Microbiol.* 2014;5:653.
116. Gortazar C, Reperant LA, **Kuiken T**, de la Fuente J, Boadella M, Martinez-Lopez B, Ruiz-Fons F, Estrada-Pena A, Drosten C, Medley G, Ostfeld R, Peterson T, Vercauteren KC, Menge C, Artois M, Schultsz C, Delahay R, Serra-Cobo J, Poulin R, Keck F, Aguirre AA, Henttonen H, Dobson AP, Kutz S, Lubroth J, Myrsterud A. Crossing the interspecies barrier: opening the door to zoonotic pathogens. *PLoS Pathog.* 2014 Jun;10(6):e1004129.
117. Wille M, van Run P, Waldenstrom J, **Kuiken T**. Infected or not: are PCR-positive oropharyngeal swabs indicative of low pathogenic influenza A virus infection in the respiratory tract of Mallard *Anas platyrhynchos*? *Vet Res.* 2014;45:53.



118. Van Bresseem, M.-F., Duignan, P.J., Banyard, A., Barbieri, M., Colegrove, K.M., de Guise, S., di Guardo, G., Dobson, A., Domingo, M., Fauquier, D., Fernandez, A., Goldstein, T., Grenfell, B., Groch, K.R., Gulland, F., Jensen, B.A., Jepson, P.D., Hall, A., **Kuiken, T.**, Mazzariol, S., Morris, S.E., Nielsen, O., Raga, J.A., Rowles, T.K., Saliki, J., Sierra, E., Stephens, N., Stone, B., Tomo, I., Wang, J., Waltzek, T., Wellehan, J.F.X. Cetacean morbillivirus: Current knowledge and future directions (2014) *Viruses*, 6 (12), pp. 5145-5181.
119. Margalida, A., Bogliani, G., Bowden, C.G.R., Donázar, J.A., Genero, F., Gilbert, M., Karesh, W.B., Kock, R., Lubroth, J., Manteca, X., Naidoo, V., Neimanis, A., Sánchez-Zapata, J.A., Taggart, M.A., Vaarten, J., Yon, L., **Kuiken, T.**, Green, R.E. One Health approach to use of veterinary pharmaceuticals (2014) *Science*, 346 (6215), pp. 1296-1298.
120. Hoffman, J.I., Simpson, F., David, P., Rijks, J.M., **Kuiken, T.**, Thorne, M.A.S., Lacy, R.C., Dasmahapatra, K.K. High-throughput sequencing reveals inbreeding depression in a natural population (2014) *Proceedings of the National Academy of Sciences of the United States of America*, 111 (10), pp. 3775-3780.
121. Gabbard, J.D., Dlugolenski, D., Van Riel, D., Marshall, N., Galloway, S.E., Howerth, E.W., Campbell, P.J., Jones, C., Johnson, S., Byrd-Leotis, L., Steinhauer, D.A., **Kuiken, T.**, Tompkins, S.M., Tripp, R., Lowen, A.C., Steel, J. Novel H7N9 influenza virus shows low infectious dose, high growth rate, and efficient contact transmission in the Guinea pig model (2014) *Journal of Virology*, 88 (3), pp. 1502-1512.
122. Short KR, Kroeze EJ, Fouchier RA, **Kuiken T.** Pathogenesis of influenza-induced acute respiratory distress syndrome. *Lancet Infect Dis.* 2014 Jan;14(1):57-69.

#### **Other – van der Eijk**

123. Verhaegh EM, Moudrous W, Buiting AG, **van der Eijk AA**, Tijssen CC. [Meningitis after a mouse bite] Meningitis na muizenbeet. *Ned Tijdschr Geneesk.* 2014;158:A7033.
124. **van der Eijk AA**, Pas SD, Cornelissen JJ, de Man RA. Hepatitis E virus infection in hematopoietic stem cell transplant recipients. *Curr Opin Infect Dis.* 2014 Aug;27(4):309-15.
125. Hassing RJ, **van der Eijk AA**, Lopes VB, Snijdewind IJ, de Man RA, Pas SD, van der Ende ME. Hepatitis E prevalence among HIV infected patients with elevated liver enzymes in the Netherlands. *J Clin Virol.* 2014 Aug;60(4):408-10.
126. HR, Pas SD, Madden RG, **van der Eijk AA**. Hepatitis e virus: current concepts and future perspectives. *Curr Infect Dis Rep.* 2014 Apr;16(4):399.
127. van den Berg B, **van der Eijk AA**, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, Dalton HR, Jacobs BC. Guillain-Barre syndrome associated with preceding hepatitis E virus infection. *Neurology.* 2014 Feb 11;82(6):491-7.
128. van Eijk JJ, Madden RG, **van der Eijk AA**, Hunter JG, Reimerink JH, Bendall RP, Pas SD, Ellis V, van Alfen N, Beynon L, Southwell L, McLean B, Jacobs BC, van Engelen BG, Dalton HR. Neuralgic amyotrophy and hepatitis E virus infection. *Neurology.* 2014 Feb 11;82(6):498-503.

#### **Other – Schutten**

129. Rokx C, Fibriani A, van de Vijver D, Verbon A, **Schutten M**, Gras L, Rijnders BJ. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort. *J Int AIDS Soc.* 2014;17(4 Suppl 3):19491.

#### **Other – Verjans**

130. Schaftenaar E, Meenken C, Baarsma GS, **Verjans GM**, Peters RP. Good visual outcome of tuberculous chorioretinitis after ART initiation in a HIV-infected patient. *Int Ophthalmol.* 2014 Dec;34(6):1263-5.
131. van Nierop GP, Hintzen RQ, **Verjans GM**. Prevalence of human Herpesviridae in cerebrospinal fluid of patients with multiple sclerosis and noninfectious neurological disease in the Netherlands. *J Neurovirol.* 2014 Aug;20(4):412-8.

#### **Other – Haagmans**

132. Burkard C, Verheije MH, Wicht O, van Kasteren SI, van Kuppeveld FJ, **Haagmans BL**, Pelkmans L, Rottier PJ, Bosch BJ, de Haan CA. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. *PLoS Pathog.* 2014 Nov;10(11):e1004502.
133. Bosch BJ, Smits SL, **Haagmans BL**. Membrane ectopeptidases targeted by human coronaviruses. *Curr Opin Virol.* 2014 Jun;6:55-60.
134. Arends P, van der Eijk AA, Sonneveld MJ, Hansen BE, Janssen HL, **Haagmans BL**. Presence of anti-interferon antibodies is not associated with non-response to pegylated interferon treatment in chronic hepatitis B. *Antivir Ther.* 2014;19(4):423-7.
135. Osinusi A, Bon D, Nelson A, Lee YJ, Poonia S, Shivakumar B, Cai SY, Wood B, **Haagmans B**, Lempicki R, Herrmann E, Sneller M, Polis M, Masur H, Kottlil S. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. *J Med Virol.* 2014 Feb;86(2):177-85.
136. Van Den Brand JMA, Smits SL, **Haagmans BL**. Pathogenesis of Middle East respiratory syndrome coronavirus. *Journal of Pathology.* 2014;235(2):175-84.

#### **Other – van Gorp**

137. Cleton NB, Reusken C, **van Gorp EC**. [The chikungunya epidemic in the Caribbean: implications for travellers and physicians] De chikungunya-epidemie in de Cariben: implicaties voor reiziger en arts. *Ned Tijdschr Geneesk.* 2014;158:A7918.
138. Limper M, van der Does Y, Brandjes DP, De Kruif MD, Rood PP, **van Gorp EC**. Procalcitonin guided antibiotic therapy in patients presenting with fever in the emergency department. *J Infect.* 2014 Oct;69(4):410-2.
139. Wagener MN, van Opstal SE, Miedema HS, Brandjes DP, Dahmen R, **van Gorp EC**, Roelofs PD. Employment-related concerns of HIV-positive people in the Netherlands: input for a multidisciplinary guideline. *J Occup Rehabil.* 2014 Dec;24(4):790-7.
140. Lodi, S., et al. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. (2014) *AIDS*, 28 (16), pp. 2461-2473

#### **Other – Martina**

141. Delang L, Segura Guerrero N, Tas A, Querat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, **Martina B**, Neyts J, van Hemert MJ, Leyssen P. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. *J Antimicrob Chemother.* 2014 Oct;69(10):2770-84.
142. Fraiser C, Papa A, Granjeaud S, Hintzen R, **Martina B**, Camoin L, Almeras L. Cerebrospinal fluid biomarker candidates associated with human WNV neuroinvasive disease. *PLoS One.* 2014;9(4):e93637.
143. **Martina BE**. Dengue pathogenesis: a disease driven by the host response. *Sci Prog.* 2014;97(Pt 3):197-214.

#### **Other – van de Vijver**

144. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Barnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, **van de Vijver DA**, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult

antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. *Lancet Glob Health*. 2014 Jan;2(1):e23-34.

#### **Other – Claassen**

145. Weenen TC, Jentink A, Pronker ES, Commandeur HR, **Claassen E**, Boirie Y, Singer P. Patient needs and research priorities in the enteral nutrition market - a quantitative prioritization analysis. *Clin Nutr*. 2014 Oct;33(5):793-801
146. Mekkes MC, Weenen TC, Brummer RJ, **Claassen E**. The development of probiotic treatment in obesity : a review. *Benef Microbes*. 2014 Mar;5(1):19-28.
147. **Claassen, E.**, Cost-benefit relation of diet and probiotics in iatrogenic bowel irregularity (IBI). *Front Pharmacol*, 2014. 5: p. 14.
148. van den Nieuwboer, M., **Claassen, E.**, Morelli, L., Guarner, F., Brummer, R. J. Probiotic and synbiotic safety in infants under two years of age. *Benef Microbes*, 2014. 5(1): p. 45-60.
149. Weenen, T. C., Commandeur H and **Claassen E.**, A critical look at medical nutrition terminology and definitions, *Trends in Food Science & Technology* (2014)
150. Fernald, K. Pennings E. and **Claassen E.** (2014) Biotechnology Commercialization Strategies: Risk and Return in interfirm cooperation. *J. Prod. Innov. Manag.* Sep 2014.

Afdeling	Opmerkingen	Indicatoren												
		1	2	3	4	5	6	7	8	9	10	11	12	
<b>Viroscience</b>	<ul style="list-style-type: none"> <li>- NL en internationale publicaties</li> <li>- Project Viruskenner voor scholieren</li> <li>- contacten met de media ivm Ebola epidemie</li> <li>- advisering NL en internationaal</li> <li>- uitzending analisten naar West-Afrika</li> <li>- Master I &amp; I opleiding</li> <li>- Samenwerking met Crucell op het gebied van Varicella Zoster Virus</li> </ul>	x	x	x	x	x							x	x